ChiCTR2400094807 版本V1.0 版本创建时间2024/12/27 15:31:27 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400094807 

最近更新日期:

Date of Last Refreshed on:

2024-12-27 15:31:20 

注册时间:

Date of Registration:

2024-12-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

牙周炎唾液菌群介导的肠道菌群紊乱促进动脉粥样硬化的机制研究

Public title:

Study on the Mechanism of Periodontitis Salivary Microbiota Mediated Gut Microbiota Dysbiosis Promoting Atherosclerosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

牙周炎唾液菌群介导的肠道菌群紊乱促进动脉粥样硬化的机制研究

Scientific title:

Study on the Mechanism of Periodontitis Salivary Microbiota Mediated Gut Microbiota Dysbiosis Promoting Atherosclerosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

黄敏 

研究负责人:

黄敏 

Applicant:

Huang Min 

Study leader:

Huang Min 

申请注册联系人电话:

Applicant telephone:

+86 189 5042 4883

研究负责人电话:

Study leader's telephone:

+86 189 5042 4883

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

283077812@qq.com

研究负责人电子邮件:

Study leader's E-mail:

283077812@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

福建省福州市鼓楼区东街134号

研究负责人通讯地址:

福建省福州市鼓楼区东街134号

Applicant address:

No. 134 East Street, Gulou District,Fuzhou City, Fujian Province

Study leader's address:

No. 134 East Street, Gulou District,Fuzhou City, Fujian Province

申请注册联系人邮政编码:

Applicant postcode:

350001

研究负责人邮政编码:

Study leader's postcode:

350001

申请人所在单位:

福州大学附属省立医院

Applicant's institution:

Fuzhou University Affiliated Provincial Hospital

研究负责人所在单位:

福建省立医院(福州大学附属省立医院)

Affiliation of the Leader:

Fujian Provincial Hospital(Fuzhou University Affiliated Provincial Hospital)

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

K2024-08-003

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

福建省立医院伦理委员会

Name of the ethic committee:

Ethics Committee of Fujian Provincial Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-08-06 00:00:00

伦理委员会联系人:

练发扬

Contact Name of the ethic committee:

Lian Fayang

伦理委员会联系地址:

福建省福州市鼓楼区东街134号

Contact Address of the ethic committee:

No. 134 East Street, Gulou District,Fuzhou City, Fujian Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 591 8821 6023

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

福建省立医院(福州大学附属省立医院)

Primary sponsor:

Fujian Provincial Hospital(Fuzhou University Affiliated Provincial Hospital)

研究实施负责(组长)单位地址:

福建省福州市鼓楼区东街134号

Primary sponsor's address:

No. 134 East Street, Gulou District,Fuzhou City, Fujian Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

南京

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京大学医学院附属口腔医院/南京大学口腔医学研究所

具体地址:

江苏省南京市玄武区中央路30号

Institution
hospital:

Nanjing Stomatological Hospital , Affiliated Hospital of Nanjing University School of Medicine/Institute of Stomatology, Nanjing University

Address:

No. 30 Central Road,Xuanwu District, Nanjing City, Jiangsu Province

经费或物资来源:

课题经费

Source(s) of funding:

Project Funding

Target disease:

Periodontitis, Atherosclerosis

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

本研究通过收集冠心病患者、牙周炎患者、冠心病伴牙周炎患者及健康志愿者的龈沟液、龈下菌斑、唾液、粪便、血液样本,并对其进行牙周专科及心内科检查,明确临床实际中,动脉粥样硬化与牙周健康之间的关系,并探讨动脉粥样硬化是否与肠道菌群变化有关,以及牙周炎相关肠道菌群的特征。研究结果将有利于揭示口腔-肠道轴在牙周炎促进动脉粥样硬化中的作用,可能发现针对性的干预靶点,同时为牙周炎与全身疾病的关联研究提供新思路。  

Objectives of Study:

In this study, we collected gingival sulcus fluid, subgingival plaque, saliva, feces, and blood samples from patients with coronary heart disease, periodontitis, coronary heart disease with periodontitis, and healthy volunteers, and conducted periodontology and cardiology examinations to clarify the relationship between atherosclerosis and periodontal health in clinical practice, and to explore whether atherosclerosis is related to changes in intestinal microbiota, as well as the characteristics of intestinal microbiota related to periodontitis. The results of this study will help to reveal the role of the oral-intestinal axis in the promotion of atherosclerosis by periodontitis, and may find targeted intervention targets, and provide new ideas for the association between periodontitis and systemic diseases.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. CHD患者的纳入标准: 冠状动脉造影显示至少一条主要冠状动脉有>=50%的稳定性狭窄或动脉阻塞。 2. 重度牙周炎患者的纳入标准: a. 年龄满18岁;口内存留>=20颗牙;因牙周炎失牙<=4颗; b. 全口牙中有附着丧失和骨吸收的位点数目>=30% c. 患者2 颗及以上患牙具有以下3 项特征:(I)探诊深度>=6 mm;(II)邻面最重位点的临床附着丧失>=5 mm;(III)影像学牙槽骨吸收至根中1/3及以上; 3. 牙周健康者的纳入标准: a. 年龄满18岁;口内存留>=20颗牙;不具有已确诊的系统性疾病; b. 口内卫生状况良好,无牙周病史或症状,探诊袋深<=3 mm,探诊出血位点(+)<=10%。

Inclusion criteria

1. CHD group: Coronary angiography shows at least one major coronary artery with >= 50% stable stenosis or arterial obstruction 2. Severe periodontitis group: a. Age 18 years and above; At least 20 natural teeth in the oral cavity; Loss of teeth due to periodontitis <= 4 teeth; b. Generalized periodontitis: >30% of sites have bone resorption and attachment loss among all teeth; c. Severe periodontitis: Two or more affected teeth PD >= 6 mm; CAL >=5 mm; RBL exceeds 1/2 of the length of the root. 3.Periodontal healthy group: 1) Age 18 years and above; At least 20 natural teeth in the oral cavity; do not have a confirmed systemic disease; 2) Periodontally healthy: clinical gingival health on an intact periodontium; The depth of the probing pocket is<= 3 mm, and the bleeding site (+) detected is <=10%.

排除标准:

a. 近6个月内接受过牙周治疗; b. 患有其他相关疾病,包括系统性疾病,如糖尿病、免疫缺陷、慢性胃肠病、胃肠道活动异常、心脑血管疾病、肾炎、血液病、类风湿性关节炎等疾病;存在其他严重口腔疾病;妊娠期或哺乳期;体重指数>=30; c. 近6个月内使用抗生素或非甾体类抗炎药,或其他影响炎症反应的药物; d. 使用烟草制品;

Exclusion criteria:

1) Received periodontal treatment in the past 6 months; 2) Suffer from systemic diseases or conditions that affect the gut microbiota, such as chronic gastrointestinal diseases, diabetes, cardiovascular, cerebrovascular diseases, hypertension, nephritis, haematological diseases, immunodeficiency, other serious oral diseases, pregnant or nursing, and obesity (BMI >= 30); 3) Received antibiotic treatment or non-steroidal anti-inflammatory drugs or other drugs which affect the inflammation reaction in the past 6 months; 4) Smokers;

研究实施时间:

Study execute time:

From 2024-10-01 00:00:00 To 2029-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-01-01 00:00:00 To 2029-12-31 00:00:00  

干预措施:

Interventions:

组别:

冠心病伴重度牙周炎组

样本量:

40

Group:

Coronary heart disease with severe periodontitis group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

冠心病牙周健康组

样本量:

40

Group:

CHD group

Sample size:

干预措施:

Periodontal health group for coronary heart disease

干预措施代码:

Intervention:

None

Intervention code:

组别:

重度牙周炎组

样本量:

40

Group:

Severe periodontitis group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

牙周健康组

样本量:

40

Group:

Periodontal health group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

福州 

Country:

China 

Province:

Fujian 

City:

Fuzhou 

单位(医院):

福建省立医院(福州大学附属省立医院) 

单位级别:

三甲 

Institution
hospital:

Fujian Provincial Hospital(Fuzhou University Affiliated Provincial Hospital)

Level of the institution:

Teriary A

测量指标:

Outcomes:

指标中文名:

菌群

指标类型:

主要指标

Outcome:

Microbiota

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢物

指标类型:

主要指标

Outcome:

Metabolics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

龈下菌斑

组织:

Sample Name:

Subgingival plaque

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

龈沟液

组织:

Sample Name:

Gingival crevicular fluid

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

唾液

组织:

Sample Name:

Saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

粪便

组织:

Sample Name:

Feces

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不涉及

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2030年后共享于网络平台,将原始数据上传到ResMan临床试验公共管理平台http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Shared on online platforms after 2030. Upload raw data to the ResMan Clinical Trial Public Management platform.http://www.medresman.org.cn/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过病例记录患者基本信息,由福州大学附属省立医院电子病历系统管理;记录样本信息及数据分析结果,由研究负责人进修数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The basic information of patients is recorded throuth case records, maaged by the electronic case system of Fuzhou University Affiliated Provincial Hospital. And the sample information and database are recorded, which is managed by the research leader.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-12-27 15:31:20